In conclusion, tislelizumab, bevacizumab, and a platinum-containing chemotherapy regimen followed by radiotherapy with maintenance therapy for newly diagnosed, high-risk, locally advanced cervical cancer patients with para-aortic lymph node metastases and PD-L1 expression demonstrated significant clinical efficacy while maintaining an excellent safety profile, with no severe adverse events observed. This evidence concerns the gene CD274 and cervical cancer.